Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody

FEBS Letters
Silvia Sánchez-MartínezJose L Nieva

Abstract

HIV-1 neutralizing monoclonal antibody (Mab) 2F5 recognizes a membrane-partitioning gp41 sequence. Just recently its capacity to react with cardiolipin has been demonstrated. Here, we have studied the specificity of Mab2F5-phospholipid interactions comparing partitioning into lipid bilayers with recognition of molecular species dispersed in solution. Using a liposome-based ELISA we demonstrate a preferential association with cardiolipin bilayers. When different soluble lysoderivatives were compared in their capacity to inhibit Mab2F5 binding to immobilized HIV-1 peptide epitope, only dilysocardiolipin resulted effective in blocking the process. Dilyso-cardiolipin also competed with native-functional gp41 for 2F5 recognition. Thus, our data support specific cardiolipin recognition by 2F5 that is not dependent on lipid bilayer assembly and involves the epitope-binding site. These findings might be of relevance for understanding the molecular basis of HIV-1 immune evasion.

References

Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·A J ConleyE A Emini
Dec 1, 1994·AIDS Research and Human Retroviruses·M PurtscherA Jungbauer
Jul 20, 1999·Annual Review of Biophysics and Biomolecular Structure·S H White, W C Wimley
Oct 12, 2000·Nature Cell Biology·M LutterX Wang
Apr 17, 2001·Annals of the Rheumatic Diseases·H GuglielmoneE Fernandez
Jul 4, 2001·The Journal of Biological Chemistry·S H WhiteK Hristova
Mar 26, 2003·The Journal of Antimicrobial Chemotherapy·Gabriela Stiegler, Hermann Katinger
Dec 4, 2003·Biophysical Journal·Asier Sáez-CiriónJosé L Nieva
May 13, 2004·The Journal of Biological Chemistry·Oihana TerronesGorka Basañez

❮ Previous
Next ❯

Citations

Oct 18, 2011·Nature Structural & Molecular Biology·Mikyung KimEllis L Reinherz
Dec 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Laurent VerkoczyBarton F Haynes
Nov 28, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Valérie MartinezUNKNOWN ALT ANRS CO15 Study Group
Dec 15, 2010·Viral Immunology·Kristina K PeachmanMangala Rao
Oct 29, 2011·Journal of Immunological Methods·Gregory J HardyStefan Zauscher
Jan 30, 2008·Vaccine·Carl R Alving, Mangala Rao
Jun 23, 2009·Virology·Andreas HinzWinfried Weissenhorn
Jan 29, 2008·Biochimica Et Biophysica Acta·Maier LorizateJosé L Nieva
Mar 14, 2009·Chembiochem : a European Journal of Chemical Biology·Ana S VeigaMarie Isabel Aguilar
Jun 24, 2008·Critical Reviews in Biochemistry and Molecular Biology·Judith M WhiteKathryn Schornberg
Sep 9, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jérôme CoutantMorgane Bomsel
Aug 3, 2019·Expert Review of Vaccines·Zachariah SternLeondios G Kostrikis
Sep 10, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Emma L MohrJack T Stapleton
Feb 19, 2017·The Journal of Biological Chemistry·Edurne RujasJosé L Nieva
Oct 19, 2019·Proceedings of the National Academy of Sciences of the United States of America·Yi WangMikyung Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antigenic Modulation

Antigenic modulation occurs when an antibody cross-links antigens on a cell surface, causing the antigens to become internalized. This can lead to therapeutic failure of monoclonal antibodies as the expression of the antigen becomes decreased on target cells. Find the latest research on antigenic modulation here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.